H
Hajime Uno
Researcher at Harvard University
Publications - 227
Citations - 11013
Hajime Uno is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 44, co-authored 201 publications receiving 8864 citations. Previous affiliations of Hajime Uno include Brigham and Women's Hospital & Stanford University.
Papers
More filters
Journal ArticleDOI
Hippocampal damage associated with prolonged glucocorticoid exposure in primates
TL;DR: The observed anatomical distribution of damage, and the cellular features of the damage agree with that observed in instances of GC-induced toxicity in the rodent hippocampus, and of stress-inducedoxicity in the primate hippocampus, suggesting that sustained GC exposure (whether due to stress, Cushings syndrome or exogenous administration) might damage the human hippocampus.
Journal ArticleDOI
On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data.
TL;DR: A simple C-statistic is presented which consistently estimates a conventional concordance measure which is free of censoring and results from numerical studies suggest that the new procedure performs well in finite sample.
Journal ArticleDOI
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
TL;DR: The relationships between SCNA levels, tumor mutations, and cancer hallmarks are examined to find that two hallmarks of cancer, cell proliferation and immune evasion, are predicted by distinct types of aneuploidy that likely act through distinct mechanisms.
Journal ArticleDOI
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
Hajime Uno,Brian Claggett,Lu Tian,Eisuke Inoue,Paul Gallo,Toshio Miyata,Deborah Schrag,Masahiro Takeuchi,Yoshiaki Uyama,Lihui Zhao,Hicham Skali,Scott D. Solomon,Susanna Jacobus,Michael Hughes,Milton Packer,Lee-Jen Wei +15 more
TL;DR: Critical concerns regarding this conventional practice of quantifying the underlying differences between groups with respect to a time-to-event end point are summarized and various well-known alternatives are discussed.
Journal ArticleDOI
Erythropoietic response and outcomes in kidney disease and type 2 diabetes
Scott D. Solomon,Hajime Uno,Eldrin F. Lewis,Kai-Uwe Eckardt,Julie Lin,Emmanuel A. Burdmann,Dick de Zeeuw,Peter Ivanovich,Andrew S. Levey,Patrick S. Parfrey,Giuseppe Remuzzi,Ajay K. Singh,Robert D. Toto,Fannie Huang,Jerome Rossert,John J.V. McMurray,Marc A. Pfeffer +16 more
TL;DR: A poor initial hematopoietic response to darbepoetin alfa was associated with an increased subsequent risk of death or cardiovascular events as doses were escalated to meet target hemoglobin levels.